WMT

124.35

+0.19%↑

COST

998.63

-0.14%↓

TGT

121.7

+1.71%↑

70.25

-4.16%↓

DG.US

120.73

+2.18%↑

WMT

124.35

+0.19%↑

COST

998.63

-0.14%↓

TGT

121.7

+1.71%↑

70.25

-4.16%↓

DG.US

120.73

+2.18%↑

WMT

124.35

+0.19%↑

COST

998.63

-0.14%↓

TGT

121.7

+1.71%↑

70.25

-4.16%↓

DG.US

120.73

+2.18%↑

WMT

124.35

+0.19%↑

COST

998.63

-0.14%↓

TGT

121.7

+1.71%↑

70.25

-4.16%↓

DG.US

120.73

+2.18%↑

WMT

124.35

+0.19%↑

COST

998.63

-0.14%↓

TGT

121.7

+1.71%↑

70.25

-4.16%↓

DG.US

120.73

+2.18%↑

Home・Akciju saraksts・Limoneira Co

Limoneira Co

Atvērts

SektorsPatēriņa aizsardzības

13.31 -0.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

13.03

Max

13.48

Galvenie mērījumi
By Trading Economics
Ienākumi	-750K -9.4M
Pārdošana	-25M 18M
EPS	-0.48
Dividenžu ienesīgums	2.28
Peļņas marža	-51.859
Darbinieki	191
EBITDA	619K -8.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+85.87% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.28% 3.82%
Nākamie ieņēmumi	2026. g. 8. jūn.
Nākamais dividenžu datums	2026. g. 10. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4.9M 246M
Iepriekšējā atvēršanas cena	14.06
Iepriekšējā slēgšanas cena	13.31

Ziņu noskaņojums

By Acuity

50%

65 / 131 Rangs Consumer defensive

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

15.42 / 15.84 Atbalsts un pretestība

Limoneira Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna

Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna

Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

Limoneira Co Prognoze

Cenas mērķis

By TipRanks

85.87% augšup

Prognoze 12 mēnešiem

Vidējais 25 USD 85.87%

Augstākais 31 USD

Zemākais 19 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Limoneira Co — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Limoneira Co — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

15.42 / 15.84Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Noskaņojums

By Acuity

65 / 131 Rangs Patēriņa aizsardzības

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Limoneira Co

Limoneira Company operates as an agribusiness and real estate development company in the United States and internationally. The company operates through three divisions: Agribusiness, Rental Operations, and Real Estate Development. It grows, processes, packs, markets, and sells lemons. The company also grows avocado, oranges, and specialty citrus and other crops, including Moro blood oranges, Cara Cara oranges, Valencia oranges, Minneola tangelos, Star Ruby grapefruit, pummelos, and wine grapes. It has approximately 3,500 acres of lemons planted primarily in Ventura, Tulare, San Luis Obispo, and San Bernardino Counties in California; and Jujuy, Argentina, as well in Yuma County, Arizona, and La Serena, Chile; 1,200 acres of avocados planted in Ventura County; 100 acres of oranges planted in Tulare County, California; and 400 acres of specialty citrus and other crops. In addition, the company rents residential housing units and commercial office buildings, as well as leases approximately 400 acres of its land to third-party agricultural tenants. Further, it is involved in the organic recycling operations; and development of land parcels, multi-family housing, and single-family homes. The company markets and sells its lemons directly to food service, wholesale, and retail customers; avocados, oranges, specialty citrus, and other crops to third-party packinghouses; and wine grapes to wine producers. Limoneira Company was founded in 1893 and is headquartered in Santa Paula, California.